{"disease":{"id":"the-neoadjuvant-therapy","name":"the neoadjuvant therapy"},"drugs":{"marketed":[{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03493880","title":"The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06288373","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04227886","title":"Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04913896","title":"CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT05455632","title":"Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07020247","title":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":184,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06794099","title":"Study on the Applicability of CCR Criteria in Rectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04264468","title":"Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT07448077","title":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":128,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT04753177","title":"The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary","has_results":false},{"nct_id":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT07198165","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05246020","title":"Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06986005","title":"The Effect of Neoadjuvant Chemotherapy on Physical Functions","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"ATİYE KAŞ ÖZDEMİR","has_results":false},{"nct_id":"NCT03650738","title":"This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04771520","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04329494","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04799639","title":"Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04511039","title":"Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07169864","title":"Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Jinsong Lu","has_results":false},{"nct_id":"NCT04815408","title":"PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07165847","title":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04929067","title":"Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":39,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07126119","title":"Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT04047693","title":"Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Pusan National University Yangsan Hospital","has_results":false},{"nct_id":"NCT05775796","title":"Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06241807","title":"Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT04221893","title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04220827","title":"Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04523818","title":"Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04183218","title":"Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07142863","title":"Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04501913","title":"Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04522336","title":"Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04391049","title":"Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT05041153","title":"Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03395847","title":"Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03918499","title":"IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04460937","title":"Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04029857","title":"Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}